Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma - PubMed (original) (raw)
. 1994 Jun 15;83(12):3654-63.
Affiliations
- PMID: 8204890
Free article
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma
X G Zhang et al. Blood. 1994.
Free article
Abstract
We report a novel, reproducible methodology which enabled 10 human myeloma cell lines (HMCL) to be obtained from each of 10 tumor samples harvested from 9 patients with extramedullary proliferation. Fresh samples were cultured with interleukin 6 (IL-6) and granulocyte macrophage-colony stimulating factor (GM-CSF) at a high cell density and resulting HMCL growth became progressively dependent on IL-6 alone, no longer requiring GM-CSF. These HMCL, which had the same immunoglobulin gene rearrangements as the patients' original myeloma cells, were designated XG-1 to XG-9. XG HMCL had a plasma cell morphology, expressed plasma cell antigen (Ag), namely cytoplasmic immunoglobulins, CD38, B-B4 Ag, and CD77, and lacked the usual B-cell Ag. They also expressed activation antigens such as CD28 with coexpression of CD28 and its ligand, B7 Ag, in four HMCL. Six HMCL expressed CD40, 4 CD23, and 5 its ligand, CD21. The XG HMCL bore adhesion molecules VLA-4 and CD44 (all 10 HMCL), VLA-5 (7 HMCL), and CD56 (4 HMCL). Finally, cytogenetic study of 8 HMCL indicated a 14q+ chromosome, and t(11,14) translocation was found in 6 of 8 and 5 of 8 HMCL, respectively. The possibility of obtaining malignant plasma cell lines reproducibly from each patient with extramedullary proliferation offers a unique tool for studying the phenotype and abnormalities of the still unidentified tumor stem cell in this disease.
Similar articles
- Cytokine gene expression in human multiple myeloma.
Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Klein B. Portier M, et al. Br J Haematol. 1993 Nov;85(3):514-20. doi: 10.1111/j.1365-2141.1993.tb03341.x. Br J Haematol. 1993. PMID: 7510989 - Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines.
Verdelli D, Mattioli M, Fabris S, Nobili L, Intini D, Guerneri S, Todoerti K, Zanella A, Deliliers GL, Lombardi L, Neri A. Verdelli D, et al. Haematologica. 2005 Nov;90(11):1541-8. Haematologica. 2005. PMID: 16266902 - Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.
Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B. Zhang XG, et al. Blood. 1990 Dec 15;76(12):2599-605. Blood. 1990. PMID: 2265252 Clinical Trial. - Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. Laï JL, et al. Blood. 1995 May 1;85(9):2490-7. Blood. 1995. PMID: 7537117 Review. - Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R. Klein B, et al. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201. Eur Cytokine Netw. 1990. PMID: 2104241 Review.
Cited by
- Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.
Chiron D, Maïga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C. Chiron D, et al. Blood Cancer J. 2013 Jun 7;3(6):e120. doi: 10.1038/bcj.2013.18. Blood Cancer J. 2013. PMID: 23749045 Free PMC article. - Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression.
Badr G, Mohany M, Abu-Tarboush F. Badr G, et al. Lipids Health Dis. 2011 Dec 16;10:236. doi: 10.1186/1476-511X-10-236. Lipids Health Dis. 2011. PMID: 22177381 Free PMC article. - Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells.
Thabard W, Collette M, Bataille R, Amiot M. Thabard W, et al. Biochem J. 2001 Aug 15;358(Pt 1):193-200. doi: 10.1042/0264-6021:3580193. Biochem J. 2001. PMID: 11485567 Free PMC article. - Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H. Hose D, et al. Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30. Haematologica. 2011. PMID: 20884712 Free PMC article. - An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.
Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B. Mahtouk K, et al. Blood. 2004 Mar 1;103(5):1829-37. doi: 10.1182/blood-2003-05-1510. Epub 2003 Oct 23. Blood. 2004. PMID: 14576062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous